Concentra Group Holdings Parent (NYSE:CON – Get Free Report) and Amarantus Bioscience (OTCMKTS:AMBS – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Profitability
This table compares Concentra Group Holdings Parent and Amarantus Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Concentra Group Holdings Parent | 8.69% | 47.81% | 7.04% |
| Amarantus Bioscience | N/A | N/A | N/A |
Earnings & Valuation
This table compares Concentra Group Holdings Parent and Amarantus Bioscience”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Concentra Group Holdings Parent | $2.16 billion | 2.04 | $166.41 million | $1.55 | 22.30 |
| Amarantus Bioscience | N/A | N/A | N/A | N/A | N/A |
Concentra Group Holdings Parent has higher revenue and earnings than Amarantus Bioscience.
Risk and Volatility
Concentra Group Holdings Parent has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Concentra Group Holdings Parent and Amarantus Bioscience, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Concentra Group Holdings Parent | 0 | 0 | 7 | 1 | 3.12 |
| Amarantus Bioscience | 0 | 0 | 0 | 0 | 0.00 |
Concentra Group Holdings Parent presently has a consensus target price of $37.00, indicating a potential upside of 7.06%. Given Concentra Group Holdings Parent’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Concentra Group Holdings Parent is more favorable than Amarantus Bioscience.
Summary
Concentra Group Holdings Parent beats Amarantus Bioscience on 8 of the 9 factors compared between the two stocks.
About Concentra Group Holdings Parent
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.
About Amarantus Bioscience
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Concentra Group Holdings Parent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concentra Group Holdings Parent and related companies with MarketBeat.com's FREE daily email newsletter.
